Susquehanna International Group
RPRX icon

Susquehanna International Group’s Royalty Pharma RPRX Stock Holding History

Susquehanna International Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Sell
26,100
-15,000
-36% -$657K ﹤0.01% 7317
2025
Q4 		$1.59M Sell
41,100
-36,700
-47% -$1.4M ﹤0.01% 6118
2025
Q3 		$2.74M Sell
77,800
-11,300
-13% -$409K ﹤0.01% 5157
2025
Q2 		$3.21M Buy
89,100
+43,900
+97% +$1.45M ﹤0.01% 4833
2025
Q1 		$1.41M Buy
45,200
+28,500
+171% +$903K ﹤0.01% 6376
2024
Q4 		$426K Sell
16,700
-6,200
-27% -$164K ﹤0.01% 9069
2024
Q3 		$648K Sell
22,900
-64,300
-74% -$1.78M ﹤0.01% 7852
2024
Q2 		$2.3M Sell
87,200
-13,300
-13% -$369K ﹤0.01% 4826
2024
Q1 		$3.05M Sell
100,500
-55,900
-36% -$1.65M ﹤0.01% 4486
2023
Q4 		$4.39M Buy
156,400
+115,500
+282% +$3.17M ﹤0.01% 3927
2023
Q3 		$1.11M Buy
40,900
+14,200
+53% +$422K ﹤0.01% 6403
2023
Q2 		$821K Buy
+26,700
New +$904K ﹤0.01% 7141
2023
Q1 		– Sell
-30,600
Closed -$1.21M – 13355
2022
Q4 		$1.21M Buy
30,600
+7,200
+31% +$301K ﹤0.01% 5776
2022
Q3 		$940K Sell
23,400
-21,500
-48% -$918K ﹤0.01% 6791
2022
Q2 		$1.89M Buy
44,900
+7,100
+19% +$291K ﹤0.01% 5030
2022
Q1 		$1.47M Sell
37,800
-57,800
-60% -$2.27M ﹤0.01% 6183
2021
Q4 		$3.81M Sell
95,600
-23,700
-20% -$921K ﹤0.01% 4218
2021
Q3 		$4.31M Buy
119,300
+18,500
+18% +$719K ﹤0.01% 4227
2021
Q2 		$4.13M Sell
100,800
-48,900
-33% -$2.08M ﹤0.01% 4379
2021
Q1 		$6.53M Sell
149,700
-30,000
-17% -$1.42M ﹤0.01% 3432
2020
Q4 		$8.99M Buy
179,700
+55,400
+45% +$2.35M ﹤0.01% 2626
2020
Q3 		$5.23M Buy
124,300
+92,500
+291% +$3.97M ﹤0.01% 2988
2020
Q2 		$1.54M Buy
+31,800
New +$1.57M ﹤0.01% 4969

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's RPRX Position: Q1 2026 in Review

Susquehanna International Group increased its Royalty Pharma (RPRX) stake by 154% in Q1 2026, buying an estimated $681K and bringing the position to 25,633 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #7355.

Susquehanna International Group first reported a position in RPRX in Q2 2020 and has held it in 20 quarters since. The position peaked at $52.8M in Q4 2024. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Susquehanna International Group held 25,633 shares of Royalty Pharma worth $1.23M as of Q1 2026.
  • Susquehanna International Group bought 15,542 Royalty Pharma shares in Q1 2026, an estimated $681K.
  • Royalty Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7355 holding.
  • Susquehanna International Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 20 quarters since.
  • Susquehanna International Group's Royalty Pharma position peaked at $52.8M in Q4 2024.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.